Clinical Trial Update: Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1 [Phase 2, Phase 3]

View source ↗

Summary

This update reports on a Phase 2/3 clinical trial evaluating the tolerability and efficacy of nicotinamide (Vitamin B3) in patients with Dominant Optic Atrophy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dominant Optic Atrophy

Drugs mentioned

• Nicotinamide (nicotinamide)

Snippet

Sponsor: University Hospital, Angers | Conditions: Nicotinamide Adverse Reaction | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING